What Technical Indicators Show About Syros Pharmaceuticals Inc. (SYRS)?

0
8
REGN
REGN

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) finished Wednesday with an addition of $0.46 to close at $6.65, an upside of 7.43 percent. An average of 1,095,082 shares of common stock have been traded in the last five days. There was a fall of -$0.43 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 481,395 shares traded, while the 50-day average volume stands at 239,858.

SYRS stock has decreased by -17.44% in the last month. The company shares reached their 1-month lowest point of $5.25 on 09/19/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $5.25 and a high of $51.95 in 52 weeks. It has reached a new high 2 times so far this year and lost -79.60% or -$25.95 in price. In spite of this, the price is down -87.20% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Insider Transactions

260 days have passed since Syros Pharmaceuticals Inc. (SYRS) last reported insider trading activity. Olson Eric R, who is Chief Scientific Officer, most recently acquired $2,208 shares at $3.47 per share on Jan 05.

Valuation Metrics

Syros Pharmaceuticals Inc. (SYRS) stock’s beta is 1.63. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 16.52, the price-to-book (PB) ratio at 13.57.

Financial Health

The quick ratio of Syros Pharmaceuticals Inc. for the three months ended June 29 was 2.40, and the current ratio was 2.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.10 and a total debt to equity ratio of 1.32 for the quarter ending June 29. Its gross profit as reported stood at $122.91 million compared to revenue of $23.49 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Syros Pharmaceuticals Inc.’s return on assets was -65.40%.

Earnings Surprise

For the three-month period that ended June 29, Syros Pharmaceuticals Inc. had $27.22 million in cash and short-term investments compared to $33.97 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$34.48 million in the quarter, while revenues of -$25.15 million were grew 34.77%. The analyst consensus anticipated Syros Pharmaceuticals Inc.’s latest quarter earnings to come in at -$4.08 per share, but it turned out to be -$5.4, a -32.40% surprise. For the quarter, EBITDA amounted to -$32.85 million. Shareholders own equity worth $63.01 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Syros Pharmaceuticals Inc. (SYRS) price momentum. RSI 9-day as of the close on 21 September was 40.08%, suggesting the stock is Neutral, with historical volatility in this time frame at 122.74%.

As of today, SYRS’s price is $6.71 -6.07% or -$0.43 from its 5-day moving average. SYRS is currently trading -17.33% lower than its 20-day SMA and -24.66% lower than its 100-day SMA. However, the stock’s current price level is -23.38% below the SMA50 and -81.27% below the SMA200.

The stochastic %K and %D were 26.42% and 24.98%, respectively, and the average true range (ATR) was 0.90. With the 14-day stochastic at 35.00% and the average true range at 0.85, the RSI (14) stands at 39.79%. The stock has reached -0.64 on the 9-day MACD Oscillator while the 14-day reading was at -0.76.

Analyst Ratings

H.C. Wainwright upgraded Syros Pharmaceuticals Inc. (NASDAQ: SYRS) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Syros Pharmaceuticals Inc. (SYRS) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SYRS, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.

What is SYRS’s price target for the next 12 months?

Analysts predict a range of price targets between $27.00 and $60.00, with a median target of $40.00. Taking a look at these predictions, the average price target given by analysts for Syros Pharmaceuticals Inc. (SYRS) stock is $43.40.

LEAVE A REPLY

Please enter your comment!
Please enter your name here